The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Open accessAbstract
Key Points: MRD assessment by sequencing is prognostic of TTP and OS in multiple myeloma patients. Among patients in complete response, MRD assessment by sequencing enables identification of 2 distinct subgroups with different TTP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“studies are therefore evaluating deeper responses in a category termed “minimal residual disease-negative” (i.e., results below the threshold for minimal residual disease) that is prognostic with regard to a rate of disease progression in a time-toevent analysis and overall survival.5,6”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [6]
In the citing paper
“Our findings were similar to findings in the context of first-line therapy 5,6 in that results below the threshold for minimal residual disease were associated with prolonged progression-free survival among patients with relapsed or refractory multiple myeloma.”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [6]
In the citing paper
“subsequent studies have recognized that minimal residual disease status may serve as a surrogate for estimating disease control and survival.5,6”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [6]
In the citing paper
“or better but have residual disease above recognized thresholds have poorer outcomes than do those who are free from detectable residual disease”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [6]
Citations
Cites
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationContinuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 741
Self-citationvan der Velden, V. H. J., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., & van Dongen, J. J. M. (2003) · Leukemia · doi:10.1038/sj.leu.2402922 · Cited by 563
Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
Matsui, W., Wang, Q., Barber, J. P., Brennan, S., Smith, B. D., Borrello, I., McNiece, I., Lin, L., Ambinder, R. F., Peacock, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3096 · Cited by 539
Cited by
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationDiagnosis and Management of Multiple Myeloma: A Review
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L. A., Tuazon, S., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,029
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Voorhees, P. M., Kaufman, J. L., Laubach, J., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 693
Metadata
- Authors
- Martinez-Lopez, J., Lahuerta, J. J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M. A., Paiva, B., Weng, L., Jiménez, C., Sopena, M., Moorhead, M., Cedena, T., Rapado, I., Mateos, M. V., Rosiñol, L., Oriol, A., Blanchard, M. J., Martínez, R., Bladé, J., San Miguel, J., Faham, M., & García-Sanz, R.
- Affiliations
- Hospital Universitario 12 de Octubre, Madrid, Spain;
- Hospital Universitario 12 De Octubre (ES)
- Sequenta, Inc., San Francisco, CA;
- Consejo Superior de Investigaciones Científicas (ES)
- Clinica Universidad de Navarra (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Hospital Clínico de Madrid, Madrid, Spain
- Clínica Universitaria de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain;
- Hospital Universitario de Salamanca-IBSAL, IBMCC-CSIC, Salamanca, Spain;
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-05-15
- Volume
- 123
- Issue
- 20
- Pages
- 3073-3079
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4023416
- OpenAlex
- W2086595383
- Semantic Scholar
- 32aece9e536b8d6ae10e42524715e909b11f6bee
- Cited by
- 425
- References
- 52
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 17 · 2022: 29 · 2021: 40 · 2020: 51 · 2019: 49 · 2018: 43 · 2017: 59 · 2016: 37 · 2015: 43 · 2014: 16
- FWCI
- 36.65
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Gredos (University of Salamanca) (publishedVersion, public-domain)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Hispana (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- multiple myeloma, minimal residual disease, deep sequencing, prognostic value, multiparameter flow cytometry, allele-specific oligonucleotide PCR, time to progression, overall survival, very good partial response, complete response
- MeSH terms
- Adult, Aged, Aged, 80 and over, Bone Marrow, Female, Humans, Male, Middle Aged, Multiple Myeloma, Prognosis, Cohort Studies, Neoplasm, Residual, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2014-01-550020
- The paper
- Martinez-Lopez, J., Lahuerta, J. J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M. A., Paiva, B., Weng, L., Jiménez, C., Sopena, M., Moorhead, M., Cedena, T., Rapado, I., Mateos, M. V., Rosiñol, L., Oriol, A., Blanchard, M. J., . . . García-Sanz, R. (2014). Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. https://doi.org/10.1182/blood-2014-01-550020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.